CEBPA and central nervous system cancer: R-2-hydroxyglutarate (R-2HG) has similar effects, which reduces MYC/CEBPA transcript stability and suppresses relevant pathways, with similar effects seen in glioma, suggesting R-2HG’s potential for targeting FTO/m6A/MYC/CEBPA signaling in FTO-high cancers [98].